Breaking News Instant updates and real-time market news.

BAX

Baxter

$63.03

-2.36 (-3.61%)

, MDT

Medtronic

$78.68

-2.13 (-2.64%)

11:35
11/10/17
11/10
11:35
11/10/17
11:35

Medical device makers fall after Citi says Amazon coming soon

Amazon.com (AMZN) is likely further ahead in accessing the medical supply chain than it is within other parts of healthcare, Citi analyst Amit Hazan told investors earlier in a research note titled "Amazon: Coming for Medtech Sooner Than You Think." The analyst believes Amazon is working with an advisory board of at least 12 large hospital systems who in total represent 5%-8% of supply purchases in the U.S. Hazan sees a high likelihood that one or more major hospital systems could announce Amazon as their distributor in the near term. Makers of medical devices are trading lower in midday trading, with Baxter (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Medtronic (MDT), Stryker (SYK) and Zimmer Biomet (ZBH) all in the red by over 1.5%. Hazan says that hospital systems he spoke to were "overwhelmingly positive" towards an Amazon entry. A number of entities predicted 20%-30% of their medical supply purchases could move to Amazon distribution within the next 24 months, Hazan wrote. healthcare i distributors Cardinal Health (CAH) and McKesson (MCK) are also trading lower in today's trading while AmerisourceBergen (ABC) is up 58c to $75.83.

BAX

Baxter

$63.03

-2.36 (-3.61%)

MDT

Medtronic

$78.68

-2.13 (-2.64%)

BDX

Becton Dickinson

$218.26

-6.22 (-2.77%)

SYK

Stryker

$152.57

-4.05 (-2.59%)

BSX

Boston Scientific

$27.97

-0.62 (-2.17%)

ZBH

Zimmer Biomet

$109.61

-2.235 (-2.00%)

CAH

Cardinal Health

$59.14

-1.42 (-2.34%)

MCK

McKesson

$138.27

-1.84 (-1.31%)

ABC

AmerisourceBergen

$75.54

0.27 (0.36%)

  • 15

    Nov

  • 28

    Nov

  • 05

    Dec

  • 14

    Dec

BAX Baxter
$63.03

-2.36 (-3.61%)

10/27/17
10/27/17
DOWNGRADE

Hold
LeMaitre downgraded to Hold on slowing growth at Benchmark
As previously reported, Benchmark analyst Raymond Myers downgraded LeMaitre (LMAT) to Hold from Buy noting that is growth has slowed from its prior "unsustainable" pace and he sees some operational challenges. In the wake of the "unexpected" mid-2016 support from Baxter's (BAX) competitive recall, he anticipates tougher 2017 comparisons, he tells investors.
07/11/17
BMOC
07/11/17
UPGRADE
BMOC
Outperform
Baxter upgraded on valuation, outlook at BMO Capital
As noted earlier, BM Capital upgraded Baxter to Outperform from Market Perform. Analyst Joanne.Wuensch upgraded the stock based on valuation and her belief that it "will raise 2017 guidance, and meaningfully increase 2020 operating margin guidance." She also expects its operating margin to continue to rise and expects that its "above peer execution will continue." .Target to $70 from $55.
08/17/17
SBSH
08/17/17
INITIATION
Target $63
SBSH
Neutral
Baxter initiated with a Neutral at Citi
Citi analyst Amit Hazan started Baxter International with a Neutral rating and $63 price target. The analyst believes further margin improvements will be more modest than the past.
10/13/17
MSCO
10/13/17
NO CHANGE
MSCO
Underweight
Baxter impact from Puerto Rico better than some had feared, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Baxter provided more details on its impact from the disaster in Puerto Rico, stating that he gets the sense production levels are currently still well below 50% of capacity, but may be fully restored to normal capacity by year end. The analyst, who estimate about a 1% headwind to sales and 4c headwind to EPS for the quarter, said the impact appears manageable and better than some had feared. However, Lewis maintains an Underweight rating on Baxter shares.
MDT Medtronic
$78.68

-2.13 (-2.64%)

10/09/17
10/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Humana (HUM) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. 2. Viacom (VIAB) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying as media and cable companies jockey "for self-preservation," Charter Communications (CHTR) will likely drop, or significantly curtail, distribution of Viacom's content. 3. PTC Therapeutics (PTCT) downgraded to Underweight from Neutral at JPMorgan with analyst Anupam Rama saying the company's valuation remains at near pre-FDA Advisory Committee meetings levels, despite multiple "mixed / inconclusive / negative" updates recently. 4. Medtronic (MDT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Larry Biegelsen saying a "lull" in major product cycles will drive below average organic sales growth over at least the next few quarters. 5. Symantec (SYMC) was downgraded to Underperform from Market Perform at Cowen and to Hold from Buy at Standpoint Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/17
BMOC
10/10/17
NO CHANGE
Target $89
BMOC
Outperform
BMO sees $250M impact on Medtronic from hurricane manufacturing disruption
BMO Capital analyst Joanne Wuensch lowered her price target for Medtronic to $89 from $92, modeling a $250M impact on manufacturing in Puerto Rico resulting from Hurricane Maria. Wuensch notes that most of the impact will occur in Q2 of FY18, also lowering her EPS target for the year to $4.63 from $4.78. The analyst kept her Outperform rating on the stock.
10/10/17
NEED
10/10/17
NO CHANGE
Target $94
NEED
Buy
Medtronic shares remain attractive despite hurricane impact, says Needham
Needham analyst Mike Matson lowered his price target on Medtronic to $94 from $95 to account for about $250M estimated negative impact from Puerto Rico manufacturing disruption due to Hurricane Maria. However, the analyst views the impact as temporary, maintaining his Buy rating given the large discount in stock price that Matson sees relative to peers. He also notes that reports of the company's "product cycle demise have been greatly exaggerated" and remains confident that Medtronic can sustain a mid-single digit revenue growth rate.
10/16/17
SBSH
10/16/17
NO CHANGE
Target $359.33
SBSH
Buy
TransEnterix not 'in the same league' as Intuitive Surgical, says Citi
Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.
BDX Becton Dickinson
$218.26

-6.22 (-2.77%)

09/22/17
09/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) initiated with an Overweight at Cantor. 2. Digital Realty (DLR) initiated with a Market Perform at William Blair. 3. PNM Resources (PNM) initiated with a Market Perform at Wells Fargo. 4. Madrigal Pharmaceuticals (MDGL) initiated with an Outperform at Evercore ISI. 5. Becton Dickinson (BDX) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
WELS
10/24/17
NO CHANGE
Target $235
WELS
Outperform
Becton Dickinson price target raised to $235 from $225 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Becton Dickinson to $235 from $225 on valuation. The analyst also continues to expect positive results from the Lutonix below-the-knee trial in 2H17, and continues to see an over 50% probability that the Lutonix BTK trial will be positive and the indication could be FDA approved in 2018.He reiterates an Outperform rating on the shares.
11/01/17
PIPR
11/01/17
NO CHANGE
Target $213
PIPR
Overweight
Becton Dickinson 'swaying away' from beats and raises, says Piper Jaffray
Piper Jaffray analyst William Quirk says that post CareFusion, Becton Dickinson is "swaying away from a consistent beat-and-raise story." His remarks follow CareFusion international website checks that continued to suggest little new outside the U.S. product launches during the quarter. The analyst modestly lowered his Street-high Q4 revenue estimate and maintains an Overweight rating on Becton Dickinson with a $213 price target. He views the pending C.R. Bard (BCR) acquisition as "very attractive."
09/22/17
WELS
09/22/17
INITIATION
Target $225
WELS
Outperform
Becton Dickinson initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Becton Dickinson (BDX) with an Outperform rating and $225 price target. The analyst sees potential upside to C.R. Bard (BCR) acquisition accretion and believes any potential impact from the hurricanes in Q4 will be short-term.
SYK Stryker
$152.57

-4.05 (-2.59%)

09/22/17
RBCM
09/22/17
NO CHANGE
RBCM
Growth investors should buy Stryker, says RBC Capital
RBC Capital analyst Glenn Novarro says that Stryker " will be the biggest share gainer in knees given its momentum in cementless and robotics." The analyst thinks that it will benefit in the near-term from Zimmer Biomet's (ZBH) supply issues. He recommends that growth investors buy Stryker.
10/27/17
WELS
10/27/17
NO CHANGE
WELS
Stryker price target raised to $166 from $160 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target on Styker to $166 from $160 after the company reported Q3 revenue that beat consensus estimates and slightly raised its FY17 organic sales growth to be in the 6.5%-7% range, up from previous guidance of "the low end" of that same range.
10/31/17
OPCO
10/31/17
NO CHANGE
Target $156
OPCO
Outperform
Stryker price target raised to $156 from $148 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Stryker to $156 from $148 on higher estimates following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/27/17
COWN
10/27/17
NO CHANGE
Target $166
COWN
Outperform
Stryker Q3 results solid despite challenges, says Cowen
Cowen analyst Joshua Jennings said Stryker reported solid Q3 results despite challenges from a Sage ship-hold and bad weather. The analyst said he is encouraged by the company's increased guidance as margins remain on track. Jennings reiterated his Outperform rating and raised his price target to $166 from $160 on Stryker shares.
BSX Boston Scientific
$27.97

-0.62 (-2.17%)

10/24/17
ADAM
10/24/17
INITIATION
Target $36
ADAM
Buy
Boston Scientific initiated with a Buy at Canaccord
Canaccord analyst Jason Mills initiated Boston Scientific with a Buy rating, citing is free cash flow and relative valuation. He believes the company is primed to deliver top and bottom-line growth above its peer group over the next few years helped by its compelling portfolio of differentiated products. Mills has a Street-high price target of $36 on Boston Scientific shares.
10/24/17
10/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at Canaccord. 2. PQ Group (PQG) was initiated with a Buy at Nomura Instinet, Jefferies, Deutsche Bank, and Citi, an Overweight at KeyBanc, and a Neutral at JPMorgan and Goldman Sachs. 3. Tronox (TROX) initiated with an Overweight at JPMorgan. 4. Equinix (EQIX) initiated with a Buy at Deutsche Bank. 5. BioTelemetry (BEAT) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/17
NEED
10/04/17
NO CHANGE
NEED
Boston Scientific deal should increase market share, says Needham
Needham analyst Mike Matson believes that Boston Scientific's acquisition of Apama Medical will enable it to increase its market share and the growth rate of its Electrophysiology business. The analyst reiterates a Buy rating on the stock.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
ZBH Zimmer Biomet
$109.61

-2.235 (-2.00%)

11/09/17
11/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Buy from Neutral at Guggenheim. 2. T-Mobile (TMUS) upgraded to Buy from Hold at Deutsche Bank with analyst Matthew Niknam saying his unchanged price target of $65 represents 17% upside. 3. NetApp (NTAP) upgraded to Overweight from Underweight at Barclays with analyst Mark Moskowitz saying he sees NetApp benefiting from market share gains in all-flash arrays and easing cloud-related headwinds over the next 6-12 months. 4. Cabot Oil & Gas (COG) upgraded to Buy from Hold at Drexel Hamilton with analyst Robert Christensen citing news the U.S. Court of Appeals for the District of Columbia has denied an emergency motion to stay the Federal Energy Regulatory Commission's authorization of the company's Atlantic Sunrise pipeline project, allowing construction to recommence. 5. Zimmer Biomet (ZBH) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
EDJN
11/09/17
UPGRADE
EDJN
Buy
Zimmer Biomet upgraded to Buy from Hold at Edward Jones
11/07/17
RBCM
11/07/17
NO CHANGE
Target $125
RBCM
Outperform
Zimmer Biomet price target lowered to $125 from $140 at RBC Capital
RBC Capital analyst Glenn Novarro lowered his price target on Zimmer Biomet to $125 after Q3 earnings, saying the company continued to suffer from market share losses that were comparable to those of the first half as well the loss of business momentum in its S.E.T. division. Novarro is keeping his Outperform rating and urging investors to remain patient longer-term, with an update on CEO announcement before the end of the year and the re-inspection of the North Campus seen as catalysts toward regaining customer confidence and accelerating topline growth.
11/06/17
RHCO
11/06/17
NO CHANGE
Target $127
RHCO
Buy
Zimmer Biomet price target lowered to $127 from $136 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Zimmer Biomet to $127 following Q3 results, citing expectations of lower assumed sales and gross margins. Nudell keeps his Buy rating, saying that while below-market performance in US knees segment was due in part to unit loss, the company expects its to improve toward the market growth rate with the resolution of supply constraints as well as the new Persona revision product sometime late in 2018.
CAH Cardinal Health
$59.14

-1.42 (-2.34%)

10/27/17
JEFF
10/27/17
NO CHANGE
JEFF
Amazon licenses likely related to medical equipment, says Jefferies
News of Amazon.com's (AMZN) receipt of wholesale pharmacy licenses drove a sell-off yesterday in pharma supply chain stocks, Jefferies analyst Brian Tanquilut tells investors in a research note. Shares of AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) fell yesterday in late afternoon trading. The analyst says that while the news strengthened investor fears about Amazon's entry into drug retailing, his due diligence indicates the licenses Amazon obtained are likely associated with its sale and distribution of medical equipment rather than prescription drugs. Tanquilut, however, recognizes that Amazon fears will overhang over prescription supply chain stocks in the near-term. He believes the impact to distributors from Amazon's professional medical device sales and distribution business remains difficult to assess.
10/10/17
COWN
10/10/17
UPGRADE
Target $189
COWN
Outperform
McKesson upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rhyee upgraded McKesson (MCK) to Outperform saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. Distributor stocks, historically, fare very well coming out of a business model transition, Rhyee tells investors in a research note. He raised his price target for the shares to $189 from $176. The analyst this morning also upgraded AmerisourceBergen (ABC) to Outperform. Rhyee prefers both McKesson and AmerisourceBergen over Market Perform-rated Cardinal Health (CAH). He lowered his price target for the latter to $74 from $77.
10/10/17
10/10/17
NO CHANGE

Correction: Cowen maintains Market Perform rating on Cardinal Health
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Cardinal Health initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Cardinal with a $72 price target and a Sector Perform rating.
MCK McKesson
$138.27

-1.84 (-1.31%)

11/09/17
FBCO
11/09/17
NO CHANGE
Target $130
FBCO
Underperform
McKesson price target lowered to $130 from $155 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for McKesson to $130 from $155 on seemingly sustained industry challenges, including lackluster script volume and drug pricing challenges. The analyst reiterates an Underperform rating on the shares.
11/01/17
NEED
11/01/17
NO CHANGE
Target $173
NEED
Buy
McKesson price target lowered to $173 from $178 at Needham
Needham analyst Kevin Caliendo lowered his price target on McKesson (MCK) to $173 despite a solid quarter, saying the positive results were overshadowed by Amazon (AMZN) receiving wholesale pharmacy licenses in 12 states. The analyst notes a 15% reversal in the stock price from its post-earnings high, also attributing the price target drop to changing investor sentiment and a a lowered terminal growth rate of 1%.
10/10/17
10/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Prudential (PRU) upgraded to Buy from Neutral at FBR Capital. 2. RBS (RBS) was upgraded to Neutral from Sell at Citi and to Neutral from Underperform at Credit Suisse. 3. Palo Alto Networks (PANW) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying he sees building traction across the company's portfolio of solutions and he views it as one of the best positioned vendors to execute on an integrated security platform story. 4. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying organic growth is likely to be better than forecast in the third quarter. 5. McKesson (MCK) upgraded to Outperform from Market Perform at Cowen with analyst Charles Rhyee saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABC AmerisourceBergen
$75.54

0.27 (0.36%)

11/06/17
NEED
11/06/17
NO CHANGE
Target $86
NEED
Buy
AmerisourceBergen price target lowered to $86 from $93 at Needham
Needham analyst Kevin Caliendo lowered his price target on AmerisourceBergen (ABC) to $86 following Q4 results and initial FY18 guidance. Caliendo says he questions expectations of 3%-5% profit growth amid the management's expectations of increased operating spending. The analyst keeps his Buy rating however, noting that the set-up for FY18 is still appealing, once year-end selling is finished and Amazon's (AMZN) plans on pharmaceutical distribution are disclosed.
10/10/17
COWN
10/10/17
UPGRADE
Target $98
COWN
Outperform
AmerisourceBergen upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rhyee upgraded AmerisourceBergen to Outperform saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. Distributor stocks, historically, fare very well coming out of a business model transition, Rhyee tells investors in a research note. He raised his price target for the shares to $98 from $88.

TODAY'S FREE FLY STORIES

DE

Deere

$139.23

2.31 (1.69%)

20:25
11/21/17
11/21
20:25
11/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

PCRX

Pacira

$42.65

0.45 (1.07%)

19:24
11/21/17
11/21
19:24
11/21/17
19:24
Recommendations
Pacira analyst commentary at BMO Capital »

October Symphony data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

  • 06

    Apr

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

19:00
11/21/17
11/21
19:00
11/21/17
19:00
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

CNX

Consol

$16.27

0.23 (1.43%)

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:52
11/21/17
11/21
18:52
11/21/17
18:52
Recommendations
TiVo, Comcast analyst commentary at JPMorgan »

ITC ruling a…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$25.35

-2.86 (-10.14%)

18:48
11/21/17
11/21
18:48
11/21/17
18:48
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Glaukos selloff due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$103.00

0.25 (0.24%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:31
11/21/17
11/21
18:31
11/21/17
18:31
Periodicals
Hulu sued for failure to offer audio service for blind subscribers, NY Post says »

Advocacy groups are suing…

DIS

Disney

$103.00

0.25 (0.24%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

TWX

Time Warner

$89.56

1.85 (2.11%)

FOX

21st Century Fox

$30.10

0.2 (0.67%)

FOXA

21st Century Fox

$30.88

0.22 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.29

0.37 (0.69%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Magna announces two share repurchase programs »

Magna International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Portola: FDA extends review period for PAS for Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

PBMD

Prima BioMed

$1.65

-0.03 (-1.79%)

18:09
11/21/17
11/21
18:09
11/21/17
18:09
Hot Stocks
Prima BioMed secures European patent grant for lead product IMP321 in cancer »

Prima BioMed announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$36.70

0.39 (1.07%)

18:06
11/21/17
11/21
18:06
11/21/17
18:06
Earnings
Copart reports Q1 non-GAAP EPS 33c, consensus 27c »

Reports Q1 revenue 419.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 19

    Dec

PCTY

Paylocity

$47.79

-0.64 (-1.32%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
Paylocity chairman sells 736,845 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDC

M.D.C. Holdings

$35.10

0.91 (2.66%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
M.D.C. Holdings declares special 8% stock dividend »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated at National Securities »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated at William Blair »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated at William Blair »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated at William Blair »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated at William Blair »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated at William Blair »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMED

Amedisys

$54.97

2.29 (4.35%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Initiation
Amedisys initiated at William Blair »

Amedisys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.